Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.

Background Molecular profiling of non-small cell lung cancer (NSCLC) is essential for therapeutic decision-making. Pleural effusion obtained by a non-invasive, repeatable procedure may provide an opportunity for molecular profiling and thereby possibly provide information enabling targeted therapy. In this study, we aimed to evaluate the diagnostic performance of pleural effusion as a specimen for molecular analysis. Methods Thirty patients with paired malignant pleural effusion and thoracic biopsy specimens were included. Clinically actionable mutations were assessed using a validated targeted next generation sequencing assay. EGFR/KRAS/ALK mutation status in thoracic biopsy specimens was tested using ARMS PCR. Results The concordance rate between gene status identified by ARMS and next-generation sequencing (NGS) analysis in the thoracic biopsy and pleural effusion samples was 86.7% (26/30). Compared with the thoracic biopsy specimens, the diagnostic performance of pleural effusion showed a sensitivity of 92.3%, a specificity of 50.0%, and a positive predictive value of 92.3%. Therefore, cases with a low percentage of tumor cells (<5%) can successfully be used to detect actionable mutations in pleural effusion specimens. Conclusions These results suggest that pleural effusions are suitable specimens for oncogene mutation analysis and enable targeted therapy for patients with advanced NSCLC.

[1]  Yifan Zhou,et al.  Molecular profiling of lung adenocarcinoma using pleural effusion specimens. , 2020 .

[2]  D. Ettinger,et al.  Molecular Profiling of Malignant Pleural Effusion in Metastatic Non‐Small‐Cell Lung Carcinoma. The Effect of Preanalytical Factors , 2017, Annals of the American Thoracic Society.

[3]  Z. Maleki,et al.  Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis , 2017, Acta Cytologica.

[4]  Di Shao,et al.  A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma , 2016, Scientific Reports.

[5]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[6]  J. M. Porcel,et al.  Clinical features and survival of lung cancer patients with pleural effusions , 2015, Respirology.

[7]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[8]  K. Aldape,et al.  Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours , 2014, British Journal of Cancer.

[9]  Dan Liu,et al.  Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma , 2014, PloS one.

[10]  Richard Bourgon,et al.  High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing , 2014, Clinical Cancer Research.

[11]  Rashmi Kanagal-Shamanna,et al.  Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics , 2014, Modern Pathology.

[12]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Chan Kwon Park,et al.  Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. , 2013, Lung cancer.

[14]  A. Marchetti,et al.  Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing , 2012, Clinical Cancer Research.

[15]  J. Subramanian,et al.  Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[17]  H. Ji,et al.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Gemma,et al.  F1000 highlights , 2010 .

[19]  William Pao,et al.  Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications , 2009, Clinical Cancer Research.

[20]  J. Shih,et al.  Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma , 2008, European Respiratory Journal.

[21]  Andrew K Stewart,et al.  Patterns of surgical care of lung cancer patients. , 2005, The Annals of thoracic surgery.